The Alliance’s blog offers a personal, inside look at our activities and perspectives on a range of timely issues. We encourage your feedback.


Author: Breanna Bishop

Date: November 22nd, 2016

On November 16, the ACT-AD (Accelerate Cure/Treatments for Alzheimer’s Disease) Coalition hosted its Ninth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md., to discuss the current state of Alzheimer’s disease treatment development.

The theme of this year’s meeting was “Starting with the End in Mind: Aligning the Science to Close Gaps in Alzheimer’s Disease Therapeutic Development,” which built upon last year’s meeting and explored the most recent Alzheimer’s research, efforts to advance biomarkers in treatment trials, and approaches to improve behavioral and psychiatric aspects of Alzheimer’s disease.



The meeting featured presentations from Richard Hodes, M.D., National Institute on Aging, Carole Ho, M.D., Denali, Vissia Viglietta, M.D., Ph.D., Biogen, and Paul Rosenberg, M.D., Johns Hopkins.

Dr. Ho, who presented on novel biomarkers and how to incorporate these biomarkers into clinical trials to accelerate drug development, noted, “The hope is to have a coordinated effort across NIH, FDA, industry, and academia to develop biomarkers that can be used across multiple pathways targeted with therapeutics for AD.”

She added, “I really liked this meeting. It was a small meeting with some critical players in the field. This format allowed for an open and collaborative discussion. It was a terrific way to have a dialogue. “

There was also a panel discussion, including experts from the public and private sectors who discussed scientific and regulatory considerations for developing more meaningful Alzheimer’s disease treatments for patients.

Dr. Rachelle Doody of Roche, who moderated the panel discussion, said, “I think it was an excellent discussion with a uniquely constituted group of people who don’t always get together, including academics, people from industry – early stage drug development, as well as late stage drug development – and people from the FDA. And I think we got a chance to explore from a lot of different angles some of the topics that we all struggle with.”

For further updates, visit the ACT-AD website.

A Tribute to a Great Scientist

Author: Dan Perry

Date: March 11th, 2008

FDA Needs More Funding to Fulfill Its Mission

Author: Cynthia Bens

Date: March 18th, 2008

Spending or Investing? -- The Silver Book & Innovation

Author: Lindsay Clarke

Date: March 26th, 2008

A Q & A with Prof. Pieter Kappetein from Medtronic

Author: Alliance Staff

Date: February 20th, 2018

The Tax Cuts and Jobs Act: What Does It Mean for Older Adults?

Author: Noel Lloyd

Date: January 19th, 2018

HROTW: Learn about Age-Related Macular Degeneration in 60 Seconds

Author: Breanna Bishop

Date: December 20th, 2017

Living Longer & Loving It

Sign up for our electronic newsletter Living Longer & Loving It